
DRB18
CAS No. 2863686-81-9
DRB18( —— )
Catalog No. M33802 CAS No. 2863686-81-9
DRB18 is a highly effective pan-class inhibitor of glucose transporter proteins (GLUT). It significantly modulates energy-related metabolism in A549 cells by inducing alterations in the abundance of metabolites associated with glucose-related pathways.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 146 | Get Quote |
![]() ![]() |
5MG | 227 | Get Quote |
![]() ![]() |
10MG | 359 | Get Quote |
![]() ![]() |
25MG | 702 | Get Quote |
![]() ![]() |
50MG | 1132 | Get Quote |
![]() ![]() |
100MG | 1485 | Get Quote |
![]() ![]() |
500MG | 2961 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameDRB18
-
NoteResearch use only, not for human use.
-
Brief DescriptionDRB18 is a highly effective pan-class inhibitor of glucose transporter proteins (GLUT). It significantly modulates energy-related metabolism in A549 cells by inducing alterations in the abundance of metabolites associated with glucose-related pathways.
-
DescriptionDRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity.
-
In VitroCell Proliferation Assay Cell Line:GLUT1-4-expressed HEK293 cell lines Concentration:0-10 μM Incubation Time:30 min Result:Reduced glucose uptake in these cell lines in a dose-dependent manner with IC50s varying from ~ 900 nM to ~ 9 μM.Cell Cycle AnalysisCell Line:A549 Concentration:5 and 10 μM Incubation Time:72 hours Result:Caused cell cycle arrest in the G1/S phase transition.Western Blot Analysis Cell Line:A549 Concentration: 5 and 10 μM Incubation Time:72 hours Result:Reduced expression of glycosylated GLUT1 and GLUT2-4 in A549 cells in a dose-dependent manner.Western Blot Analysis Cell Line:A549 Concentration:5 and 10 μM Incubation Time:72 hours Result:Reduced expression of glycosylated GLUT1 and GLUT2-4 in A549 cells in a dose-dependent manner.
-
In VivoAnimal Model:Male NU/J nude mice (3-4 weeks; tumor cell-injected) Dosage:10 mg/kg Administration:IP; thrice a week for 5 weeks Result:The tumors were 44% smaller by volume and 43% smaller by weight, also showed DRB18 decreased expression of GLUT1-4 (Fig. 5f) and reduced proliferative capacity within the xenografted tumor.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptortransporter
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2863686-81-9
-
Formula Weight382.88
-
Molecular FormulaC22H23ClN2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (130.59 mM; Ultrasonic (<60°C)
-
SMILESCC1=C(C=C(C=C1)CNC2=C(C=C(C=C2)Cl)NCC3=CC(=C(C=C3)C)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shriwas P, Roberts D, Li Y, et al. A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism. Cancer Metab. 2021;9(1):14. Published 2021 Mar 26.?
molnova catalog



related products
-
2-Methylbenzene-1-su...
Used for saccharin, pharmaceutical intermediates, etc.
-
Isokaempferide
Isokaempferide shows hepatoprotective, antiproliferative, and anti-inflammatory effects, the anti-inflammatory effects can be explained, at least in part, by reducing neutrophil degranulation, myeloperoxidase activity, mediators as well as TNF-alpha secretion.
-
16-anhydro-b-D-Gluco...
16-anhydro-b-D-Glucose (Levoglucosan) is an anhydrohexose that is the 16-anhydro-derivative of beta-D-glucopyranose. It is formed from the pyrolysis of carbohydrates such as starch and cellulose. Levoglucosan can also be utilized in the synthesis of chiral polymers such as unhydrolysable glucose polymers.